Effects of GLP-1 on appetite and weight

GLP-1R Agonism Enhances Adjustable Gastric Banding in Diet-Induced Obese Rats

(2013) Kirk M. Habegger et al.   DIABETES

Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

(2013) A. E. Butler et al.   DIABETES

Contribution of Endogenous Glucagon-Like Peptide 1 to Glucose Metabolism After Roux-en-Y Gastric Bypass

(2013) M. Shah et al.   DIABETES

Vertical Sleeve Gastrectomy Is Effective in Two Genetic Mouse Models of Glucagon-Like Peptide 1 Receptor Deficiency

(2013) H. E. Wilson-Perez et al.   DIABETES

Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes: Analysis of a randomized control trial comparing surgery with intensive medical treatment

(2013) S. R. Kashyap et al.   DIABETES CARE

GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases

(2013) Flavius Zoicas et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Sleeve gastrectomy: an ideal choice for T2DM

(2013) Michel Gagner   Nature Reviews Endocrinology

Glucagon-like peptide 1 and appetite

(2013) Megan J. Dailey et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

The Effect of Glucagon-Like Peptide-1 Receptor Agonist Therapy on Body Mass Index in Adolescents With Severe Obesity

(2013) Aaron S. Kelly et al.   JAMA Pediatrics

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

(2012) John B Buse et al.   LANCET

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia

(2011) B. Gallwitz et al.   DIABETES CARE

Effects of Exenatide on Measures of  -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

(2011) M. C. Bunck et al.   DIABETES CARE

Disassociation between Preprandial Gut Peptide Release and Food-Anticipatory Activity

(2011) Megan J. Dailey et al.   ENDOCRINOLOGY

Changes in Differential Functional Magnetic Resonance Signals in the Rodent Brain Elicited by Mixed-Nutrient or Protein-Enriched Meals

(2011) David K. Min et al.   GASTROENTEROLOGY

Hyperphagia and Increased Fat Accumulation in Two Models of Chronic CNS Glucagon-Like Peptide-1 Loss of Function

(2011) J. G. Barrera et al.   JOURNAL OF NEUROSCIENCE

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

(2010) M. C. Bunck et al.   DIABETES CARE

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

(2010) A. Garber et al.   DIABETES OBESITY & METABOLISM

Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying

(2010) Mathias Nicolaus et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors

(2010) A. Amato et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Stimulation of incretin secretion by dietary lipid: is it dose dependent?

(2009) Stephanie M. Yoder et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

(2009) Richard Bergenstal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

(2009) J. Jendle et al.   DIABETES OBESITY & METABOLISM

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Meal-Anticipatory Glucagon-Like Peptide-1 Secretion in Rats

(2009) Torsten P. Vahl et al.   ENDOCRINOLOGY

Gastrointestinal hormone actions in the central regulation of energy metabolism: potential sensory roles for the circumventricular organs

(2009) T D Hoyda et al.   INTERNATIONAL JOURNAL OF OBESITY

Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia

(2009) Adam M. Deane et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Vagal Nerve Function in Obesity: Therapeutic Implications

(2009) John G. Kral et al.   WORLD JOURNAL OF SURGERY

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

(2008) T MORETTO et al.   CLINICAL THERAPEUTICS

Acute Effects of Glucagon-Like Peptide-1 on Hypothalamic Neuropeptide and AMP Activated Kinase Expression in Fasted Rats

(2008) Sanghee SEO et al.   ENDOCRINE JOURNAL

Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms

(2008) Elisabeth B. Rüttimann et al.   ENDOCRINOLOGY

Effect of Weight Loss by Gastric Bypass SurgeryVersusHypocaloric Diet on Glucose and Incretin Levels in Patients with Type 2 Diabetes

(2008) Blandine Laferrère et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Nutritional regulation of glucagon-like peptide-1 secretion

(2008) Gwen Tolhurst et al.   JOURNAL OF PHYSIOLOGY-LONDON